164 related articles for article (PubMed ID: 21255134)
1. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.
Christersson C; Oldgren J; Wallentin L; Siegbahn A
J Intern Med; 2011 Sep; 270(3):215-23. PubMed ID: 21255134
[TBL] [Abstract][Full Text] [Related]
2. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
[TBL] [Abstract][Full Text] [Related]
3. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
Christersson C; Oldgren J; Bylock A; Siegbahn A; Wallentin L
Eur Heart J; 2007 Mar; 28(6):692-8. PubMed ID: 17314111
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
[TBL] [Abstract][Full Text] [Related]
5. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
Larsen SB; Grove EL; Kristensen SD; Hvas AM
Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
[TBL] [Abstract][Full Text] [Related]
6. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
[TBL] [Abstract][Full Text] [Related]
7. The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.
Christersson C; Johnell M; Siegbahn A
Thromb Res; 2010 Oct; 126(4):e327-33. PubMed ID: 20451956
[TBL] [Abstract][Full Text] [Related]
8. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
[TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
11. Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer.
Dymicka-Piekarska V; Matowicka-Karna J; Gryko M; Kemona-Chetnik I; Kemona H
Thromb Res; 2007; 120(4):585-90. PubMed ID: 17169411
[TBL] [Abstract][Full Text] [Related]
12. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
Lim HS; Blann AD; Lip GY
Circulation; 2004 Jun; 109(21):2524-8. PubMed ID: 15136493
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
16. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
Nadar S; Blann AD; Lip GY
Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942
[TBL] [Abstract][Full Text] [Related]
17. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Wallentin L; Wilcox RG; Weaver WD; Emanuelsson H; Goodvin A; Nyström P; Bylock A;
Lancet; 2003 Sep; 362(9386):789-97. PubMed ID: 13678873
[TBL] [Abstract][Full Text] [Related]
18. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Harenberg J; Jörg I; Weiss C
Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran: a new oral anticoagulant.
Hrebickova L; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
J Thromb Haemost; 2005 Oct; 3(10):2245-53. PubMed ID: 16194202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
